CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSEDBrickell Biotech, Inc. • March 9th, 2021 • Biological products, (no disgnostic substances)
As you know, pursuant to the Letter Agreement for Supply of [***] API - First Amendment ("First API Payment Letter Agreement"), Brickell Biotech, Inc. ("Brickell") paid Kaken Pharmaceutical Co., Ltd. ("Kaken") for [***] out of a total of [***] API that Kaken delivered to Brickell pursuant to the Clinical Supply Agreement entered into between Brickell and Kaken dated as of July 30, 2019 ("CSA"). Currently, pursuant to the CSA and the First API Payment Letter Agreement, Brickell owes Kaken the following amounts:
BRICKELL BIOTECH, INC. Incentive Stock Option Award AgreementIncentive Stock Option Award Agreement • March 9th, 2021 • Brickell Biotech, Inc. • Biological products, (no disgnostic substances) • Delaware
Brickell Biotech, Inc. (the “Company”), pursuant to its 2020 Omnibus Long-Term Incentive Plan (the “Plan”), hereby grants an Option to purchase shares of the Company’s common stock to you, the Participant named below. The terms and conditions of the Option Award are set forth in this Incentive Stock Option Award Agreement (the “Agreement”), consisting of this cover page and the Terms and Conditions on the following pages, and in the Plan document, a copy of which has been provided to you. Any capitalized term that is used but not defined in this Agreement shall have the meaning assigned to it in the Plan as it currently exists or as it is amended in the future.
